TEVA-TERAZOSIN TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE)

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

G04CA03

INN (Tên quốc tế):

TERAZOSIN

Liều dùng:

1MG

Dạng dược phẩm:

TABLET

Thành phần:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 1MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

1400

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ALPHA-ADRENERGIC BLOCKING AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0136978001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

1998-02-05

Đặc tính sản phẩm

_TEVA-TERAZOSIN Product Monograph Page 1 of 40 _
PRODUCT
MONOGRAPH
PR
TEVA-TERAZOSIN
Terazosin Tablets, Teva Standard
1 mg, 2 mg, 5 mg and 10
m
g
Terazosin (as terazosin hydrochloride)
Antihypertensive
Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Teva Canada Limited
Date of Revision:
30 Novopharm Court
December 19, 2014
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
SUBMISSION CONTROL NUMBER: 174788
_TEVA-TERAZOSIN Product Monograph Page 2 of 40 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
9
DRUG INTERACTIONS
.............................................................................................................................14
DOSAGE AND ADMINISTRATION
.........................................................................................................15
OVERDOSAGE
...........................................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................17
STORAGE AND STABILITY
....................................................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......